Based on 4 Wall Street analysts offering 12 month price targets for Amphastar Pharmaceuticals in the last 3 months. The average price target is $61.33 with a high forecast of $70.00 and a low forecast of $48.00. The average price target represents a 31.08% change from the last price of $46.79.
Main Points:
Future Financial Performance: Amphastar anticipates specific trends in financial growth, market expansion, and product sales, though these are subject to change.
Product Development and Regulatory Approvals: The company expects progress in product portfolio development, including FDA filings and approvals, particularly related to its ANP DMFs and other pipeline products.
BAQSIMI® Acquisition: Amphastar projects potential benefits and revenue growth from the acquisition of BAQSIMI®, though it acknowledges uncertainties in the integration process and long-term impact.
Clinical Trials: The timing and outcomes of clinical trials are expected to influence future business directions, though these outcomes are uncertain.
Market Expansion and Sales Strategy: Amphastar plans to expand its market presence and enhance sales and marketing efforts, particularly for branded products and biosimilars.
Risk and Uncertainty: The statement highlights that there are numerous risks and uncertainties that could cause actual results to differ from current expectations, many of which are beyond the company's control.
Caution Against Over-Reliance: The statement advises against placing undue reliance on these forward-looking statements due to the inherent risks and uncertainties involved.
Technical
Price has broken its downward trend and is showing increased buying pressure, we remain cautious on this and will scale in slowly.
Main Points:
Future Financial Performance: Amphastar anticipates specific trends in financial growth, market expansion, and product sales, though these are subject to change.
Product Development and Regulatory Approvals: The company expects progress in product portfolio development, including FDA filings and approvals, particularly related to its ANP DMFs and other pipeline products.
BAQSIMI® Acquisition: Amphastar projects potential benefits and revenue growth from the acquisition of BAQSIMI®, though it acknowledges uncertainties in the integration process and long-term impact.
Clinical Trials: The timing and outcomes of clinical trials are expected to influence future business directions, though these outcomes are uncertain.
Market Expansion and Sales Strategy: Amphastar plans to expand its market presence and enhance sales and marketing efforts, particularly for branded products and biosimilars.
Risk and Uncertainty: The statement highlights that there are numerous risks and uncertainties that could cause actual results to differ from current expectations, many of which are beyond the company's control.
Caution Against Over-Reliance: The statement advises against placing undue reliance on these forward-looking statements due to the inherent risks and uncertainties involved.
Technical
Price has broken its downward trend and is showing increased buying pressure, we remain cautious on this and will scale in slowly.
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。